Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab

Today, 9:13 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)

ABBV

1 minute read

Surmodics Raises FY21 Adj. EPS Guidance From $0.10-$0.35 To $0.16-$0.31 vs $0.25 Est.

By Bill Haddad

Today, 9:13 AM

As a result of our operating performance in the first nine months of fiscal 2021, we are raising our full-year revenue guidance for fiscal 2021. We are increasing our fiscal 2021 revenue expectations to a range of $103.5

SRDX

1 minute read

Surmodics Q3 Adj. EPS $(0.17), Inline, Sales $23.87M Beat $23.31M Estimate

By Bill Haddad

Today, 9:13 AM

Surmodics (NASDAQ:SRDX) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 180.95 percent decrease over earnings of $0.21 per share from the same period last year. The

SRDX

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

By Shanthi Rexaline

Today, 9:13 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

1 minute read

Recap: Surmodics Q3 Earnings

By Benzinga Insights

Today, 9:13 AM

Shares of Surmodics (NASDAQ:SRDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 180.95% year over year to ($0.17), which were in line with the estimate of ($0.17).

SRDX